Risultati di ricerca
Naomi Allen is a Professor in Epidemiology, based in the Clinical Trial Service Unit and Epidemiological Studies Unit. She joined UK Biobank as Senior Epidemiologist in 2011, and became Chief Scientist in 2019, where she is responsible for following-up participants both through linkage with routine health-related datasets, and through web-based ...
- Overview
- Jobs
Download PDF
As an epidemiologist at Oxford University, Naomi Allen was frustrated with the field’s slow progress towards unravelling the causes of disease. Massive and detailed datasets are key to these epidemiological investigations, but large-scale cohorts are hard to access and tend to be disjointed and incomplete. So when a chance to join the UK Biobank arose, she jumped. “Before the launch of the UK Biobank, there wasn't really a large-scale study that provided access to genomic data, lifestyle data and health outcomes all in one place. That was definitely a driver for me, in wanting to help create a resource for the wider research community,” she recalls.
The UK Biobank now delivers just this. First proposed in 2002, it started collecting biological samples and in-depth environmental and lifestyle data from half a million participants in the UK in 2006. Over 30,000 industry and academic researchers worldwide mine this dataset for insight into all aspects of health and disease — analysing whole-exome and whole-genome sequences, biochemical markers, MRI images, health records and more. These researchers have already published 6,000 papers drawing on these data to identify everything from new drug targets to the impact of COVID-19 on the brain. “It's a hard job just to keep up with them all,” says Allen.
Given the size, breadth and depth of the UK Biobank’s longitudinal dataset, its outputs are set to grow exponentially. But its biggest strength is arguably the ease of access to the data, adds Allen. “Without allowing the best minds in the world access to the data, you'll never be able to maximize the utility of it.”
What research findings showcase the drug discovery potential of the UK Biobank?
That's a tough question. Last year alone, there were 1,700 peer-reviewed publications that used data from the UK Biobank. But there are definitely a few key highlights that I would pick out.
Attending Physician (m/f/d)
The Institute of Transfusion Medicine – Transfusion Centre headed by Univ.-Prof. Dr. med. Daniela S. Krause is hiring: Mainz, Rheinland-Pfalz (DE) University of Mainz
NIH Cancer Postdoc Fellowship
Train with world-renowned cancer researchers at NIH? Consider joining the Center for Cancer Research (CCR) at the National Cancer Institute Bethesda, Maryland (US) NIH National Cancer Institute (NCI)
Postdoctoral Fellow (PhD)
Houston, Texas (US) Baylor College of Medicine (BCM)
- Asher Mullard
Professor, University of oxford - Cited by 63,990 - Cancer Epidemiology - record linkage
29 mar 2022 · Published in. Threshold Ventures. ·. 9 min read. ·. Mar 29, 2022. -- I had dedicated my career to innovating in healthcare so when this opportunity came along, I just knew it was the thing I must...
- Threshold Ventures
29 mar 2022 · Founded by leading digital health entrepreneurs Naomi Allen and Giovanni Colella, MD, the company is backed by leading investors GV (formerly Google Ventures), KKR, Oak HC/FT, and Threshold.
Naomi Allen is the Co-founder and CEO at Brightline. Additionally, Naomi Allen has had 6 past jobs including Vice President, Product at Castlight Health. Brightline Co-founder and CEO Oct 2019. Board and Advisor Roles. Number of Current Board & Advisor Roles 1. Naomi Allen is the Board Member at Bright Healthcare.
14 dic 2023 · I sat down with Professor Naomi Allen, Chief Scientist at UK Biobank, to find out why this dataset is so valuable, and why it’s so important that these sequences are whole genomes, rather than just genes. Naomi: Whole genome sequencing enables researchers to look at all of the genetic variation across the entire genome.
